Market Overview

Leerink Swann Upgrades MedAssets To Outperform

Related MDAS
MedAssets Expands Purchased Services Capabilities to Further Unlock Untapped Savings Opportunities
Benzinga's Top Downgrades

Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform.

The target price for MedAssets is set to $26.

MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.

MedAssets' shares rose 0.28% to close at $21.25 yesterday.

Latest Ratings for MDAS

Aug 2015Topeka CapitalDowngradesBuyHold
Jul 2015KeyBancDowngradesOverweight
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Leerink SwannUpgrades Analyst Ratings


Related Articles (MDAS)

Get Benzinga's Newsletters